Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seetal Dodd

Showing results (191-200 of 251) with videos related to

Pageof 26
Sort By:
Biological Psychiatry|December 25, 2012
Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and functionJason M Hodge, Yiming Wang, Michael Berk, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|November 29, 2019
Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled TrialMelanie M Ashton, Mohammadreza Mohebbi, Alyna Turner, et al.
Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology|March 26, 2019
Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive <i>Garcinia mangostana</i>Linn. (Mangosteen) Pericarp for SchizophreniaAlyna Turner, John J McGrath, Olivia M Dean, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 3, 2022
The role of metformin as a treatment for neuropsychiatric illnessSeetal Dodd, Luba Sominsky, Dan Siskind, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|December 23, 2020
Adjunctive <i>Garcinia mangostana</i> Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: Péricarpe d'appoint Garcinia mangostana Linn (mangoustan) pour la schizophrénie : un essai d'efficacité de 24 semaines, à double insu, randomisé et contrôlé par placeboAlyna Turner, Andrea Baker, Olivia M Dean, et al.
Acta Psychiatrica Scandinavica|July 13, 2024
Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta-analysisAnna Giménez-Palomo, Anjli K Chamdal, Natalie Gottlieb, et al.
Acta Neuropsychiatrica|November 12, 2014
The impact of age at onset of bipolar I disorder on functioning and clinical presentationFrances Biffin, Steven Tahtalian, Kate Filia, et al.
The Medical Journal of Australia|August 18, 2010
From neuroprogression to neuroprotection: implications for clinical careMichael Berk, Philippe Conus, Flávio Kapczinski, et al.
Journal of Affective Disorders|April 13, 2015
Factors influencing insulin resistance in relation to atherogenicity in mood disorders, the metabolic syndrome and tobacco use disorderChiara Cristina Bortolasci, Heber Odebrecht Vargas, Sandra Odebrecht Vargas Nunes, et al.
The International Journal of Neuropsychopharmacology|February 23, 2018
Mechanisms Underpinning the Polypharmacy Effects of Medications in PsychiatryChiara C Bortolasci, Briana Spolding, Edward Callaly, et al.
Pageof 26

Showing results (191-200 of 251) with videos related to

Sort By:
Pageof 26
Biological Psychiatry|December 25, 2012
Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and functionJason M Hodge, Yiming Wang, Michael Berk, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|November 29, 2019
Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled TrialMelanie M Ashton, Mohammadreza Mohebbi, Alyna Turner, et al.
Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology|March 26, 2019
Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive <i>Garcinia mangostana</i>Linn. (Mangosteen) Pericarp for SchizophreniaAlyna Turner, John J McGrath, Olivia M Dean, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 3, 2022
The role of metformin as a treatment for neuropsychiatric illnessSeetal Dodd, Luba Sominsky, Dan Siskind, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|December 23, 2020
Adjunctive <i>Garcinia mangostana</i> Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: Péricarpe d'appoint Garcinia mangostana Linn (mangoustan) pour la schizophrénie : un essai d'efficacité de 24 semaines, à double insu, randomisé et contrôlé par placeboAlyna Turner, Andrea Baker, Olivia M Dean, et al.
Acta Psychiatrica Scandinavica|July 13, 2024
Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta-analysisAnna Giménez-Palomo, Anjli K Chamdal, Natalie Gottlieb, et al.
Acta Neuropsychiatrica|November 12, 2014
The impact of age at onset of bipolar I disorder on functioning and clinical presentationFrances Biffin, Steven Tahtalian, Kate Filia, et al.
The Medical Journal of Australia|August 18, 2010
From neuroprogression to neuroprotection: implications for clinical careMichael Berk, Philippe Conus, Flávio Kapczinski, et al.
Journal of Affective Disorders|April 13, 2015
Factors influencing insulin resistance in relation to atherogenicity in mood disorders, the metabolic syndrome and tobacco use disorderChiara Cristina Bortolasci, Heber Odebrecht Vargas, Sandra Odebrecht Vargas Nunes, et al.
The International Journal of Neuropsychopharmacology|February 23, 2018
Mechanisms Underpinning the Polypharmacy Effects of Medications in PsychiatryChiara C Bortolasci, Briana Spolding, Edward Callaly, et al.
Pageof 26